Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + Iberdomide in Relapsed/Refractory Multiple Myeloma
NCT06215118Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of elranatamab in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 90 days. Started Feb 2024; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06215118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215118.